medigraphic.com
Instituto Nacional de Salud Pública

2018, Number 6

<< Back Next >>

salud publica mex 2018; 60 (6)

Alternative HPV vaccination schedules in Latin America

Robles C, Hernández ML, Almonte M

Language: English
References: 48
Page: 693-702
PDF size: 361.99 Kb.


ABSTRACT

In 2008, the first HPV vaccination program in Latin America started in Panama, targeting girls aged 10-11 years with a 3-dose vaccine schedule, an initiative that was to be followed by other Latin American countries after local feasibility and population acceptability evaluations were completed. A 3-dose vaccine regimen over six months was originally chosen for HPV vaccines, copying the Hepatitis B vaccine schedule (0, 1-2, 6 months). Alternative vaccine schedules have been proposed afterwards based on: i) noninferior immunogenicity or immune response levels compared to those at which clinical efficacy has been proven (i.e., those observed in a 3-dose HPV vaccine schedule in women aged 15-26), and, ii) proven efficacy in clinical trials and/or effectiveness among women who were provided less than three doses due to a lack of adherence to a 3-dose vaccine schedule. In 2014, based on the available evidence and the potential increase in coverage by expansion of vaccination target groups, particularly in low and middle income countries (LMIC), the World Health Organization recommended a 2-dose schedule with at least a 6-month interval between doses for females up to 15 years of age and a 3-dose schedule for older women. More recently, it has been suggested that 1-dose HPV vaccination schemes may provide enough protection against HPV infection and may speed up the introduction of HPV vaccination in LMIC, where most needed.


REFERENCES

  1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer, 2013 [cited 2014, Jan 12]. Available from: http:// globocan.iarc.fr

  2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-9. https://doi.org/10.1002/ (SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F

  3. Almonte M, Sasieni P, Cuzick J. Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccines. Best Pract Res Clin Obstet Gynaecol. 2011;25(5):617-29. https://doi. org/10.1016/j.bpobgyn.2011.05.003

  4. Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PloS One. 2013;8(7):e68329. https://doi.org/10.1371/journal.pone.0068329

  5. Lehtinen M, Dillner J. Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol. 2013;10(7):400-10. https://doi. org/10.1038/nrclinonc.2013.84

  6. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711-23. https://doi.org/10.1056/ NEJMoa1405044

  7. Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population- level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565-80. https://doi.org/10.1016/S1473-3099(14)71073-4

  8. Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63(4):519-27. https://doi.org/10.1093/cid/ciw354

  9. Tambini G, Andrus JK, Fitzsimmons JW, Roses-Periago M. Regional immunization programs as a model for strengthening cooperation among nations. Rev Panam Salud Publica. 2006;20(1):54-9. https://doi.org/10.1590/ S1020-49892006000700012

  10. Penny M, Bartolini R, Mosqueira NR, LaMontagne DS, Mendoza MA, Ramos I, et al. Strategies to vaccinate against cancer of the cervix: feasibility of a school-based HPV vaccination program in Peru. Vaccine. 2011;29(31):5022-30. https://doi.org/10.1016/j.vaccine.2011.04.078

  11. Arrossi S, Maceira V, Paolino M, Sankaranarayanan R. Acceptability and uptake of HPV vaccine in Argentina before its inclusion in the immunization program: a population-based survey. Vaccine. 2012;30(14):2467-74. https://doi.org/10.1016/j.vaccine.2012.01.032

  12. Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4(7):e453-63. https://doi.org/10.1016/S2214-109X(16)30099-7

  13. Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine. 2012;30(Suppl 5):F157-67. https://doi. org/10.1016/j.vaccine.2012.06.091

  14. Duval B, Gilca V, Sauvageau C (eds.). Advice of the Institut National de Santé Publique Du Québec on Human Papillomavirus Vaccines. Montréal, Québec: Institut National de Santé Publique du Québec, 2008 [cited 2017 Feb, 9]. Available from: http://www.deslibris.ca/ID/213867

  15. Dubé È, Institut National de Santé Publique du Québec, Direction des Risques Biologiques Environnementaux et Occupationnels, Comité sur l’immunisation du Québec. Prevention by vaccination of diseases attributable to the human papilloma virus in Quebec. Montréal, Québec: Institut National de Santé Publique du Québec, Direction des Risques Biologiques, Environnementaux et Occupationnels, 2008 [cited 2017, Feb 9]. Available from: http://www.deslibris.ca/ID/214673

  16. Dobson SRM, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793-802. https://doi.org/10.1001/jama.2013.1625

  17. Gilca V, Sauvageau C, Boulianne N, De Serres G, Crajden M, Ouakki M, et al. The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine. Hum Vaccines Immunother. 2015;11(3):732-8. https://doi.org/10.1080/21645515.2015.1011570

  18. Lazcano-Ponce E, Salmerón-Castro J, García-Carrancá A, Aranda-Flores C, Madrid-Marina V, Gómez-Altamirano CM, Martínez-Montañez OG. Recomendaciones para la definición de la política de vacunación contra el virus del papiloma en México. Salud Publica Mex. 2009;51(4):336-41.

  19. Ministerio de Salud y Protección Social de Colombia. Vacunación contra el Virus Papiloma humano - VPH en Colombia, para la prevención del cáncer de cuello uterino y verrugas genitales. Bogotá: Munsalud, 2012 [cited 2017, Jan 30]. Available from: https://www.minsalud.gov.co/sites/rid/ Lists/BibliotecaDigital/RIDE/IA/INCA/1-vacunacion-contra-virus-papiloma% 20humano-verrugas-genitales.pdf

  20. Ministério da Saúde. Presidente Dilma e ministro Chioro iniciam vacinação contra HPV. Ministério da Saúde: Portal da Saúde, 2014 [cited 2017 Feb, 9]. Available from: http://portalsaude.saude.gov.br/index.php/ cidadao/principal/agencia-saude/10035-postos-de-saude-e-escolas-iniciamvacinacao- contra-hpv

  21. World Health Organization. Human papillomavirus vaccines: WHO position paper. Wkly Epidemiol Rec. 2014;89(43):465-92.

  22. Ministerio de Salud Pública de Ecuador. Vacuna contra el virus del papiloma humano previene cáncer uterino en el Ecuador. Quito: Ministerio de Salud Pública, 2014 [cited 2017, Oct 20]. Available from: http://www.salud. gob.ec/vacuna-contra-el-virus-del-papiloma-humano-previene-canceruterino- en-el-ecuador/

  23. Ministerio de Salud Pública de República Dominicana. Resolución no. 000023 que incorpora la vacuna contra el virus del papiloma humano (HPV) al esquema basico de inmunización del programa ampliado de inmunización. Santo Domingo: Ministerio de Salud Pública, 2016 [cited 2017, Oct 10]. Available from: http://www.msp.gob.do/oai/documentos/ Resoluciones/2016/RESOLUCION-000023-QUE%20INCORPORA%20 LA%20VACUNA%20CONTRA%20EL%20VIRUS%20ZICA%20DEL%20 PAPILOMA%20HUMANO%20HPV%20EL%20ESQUEMA%20BASICO%20 DE%20INMUNIZACION%20DEL%20PROGRAMA%20AMPLIADO%20 DE%20INMUNIZACION.pdf

  24. Ministerio de Salud, Gobierno de Chile. Vacunación contra el Virus del Papiloma Humano. Santiago: Ministerio de Salud, 2017 [cited 2017, Oct 20]. Available from: http://web.minsal.cl/vacunacion-contra-el-virus-delpapiloma- humano/

  25. Secretaría de Salud. Proyecto de Norma Oficial Mexicana PROYNOM- 036-SSA2-2014, Prevención y control de enfermedades. Aplicación de vacunas, toxoides, faboterápicos (sueros) e inmunoglobulinas en el humano. Gobierno de la República: DOF, 2014 [cited 2017, Feb 9]. Available from: http://www.dof.gob.mx/nota_detalle.php?codigo=5369071&fec ha=21/11/2014

  26. Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011;7(12):1374- 86. https://doi.org/10.4161/hv.7.12.18322

  27. Romanowski B, Schwarz TF, Ferguson L, Peters K, Dionne M, Behre U. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study. Hum Vaccines Immunother. 2016;12(1):20-9. https://doi.org/10.1080/21645515.2015.1065363

  28. Lazcano-Ponce E, Stanley M, Muñoz N, Torres L, Cruz-Valdez A, Salmerón J . Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine. 2014;32(6):725-32. https://doi.org/10.1016/j.vaccine.2013.11.059

  29. Huang LM, Puthanakit T, Cheng-Hsun C, Ren-Bin T, Schwarz T, Pellegrino A, et al. Sustained immunogenicity of 2-dose human papillomavirus 16/18 AS04-adjuvanted vaccine schedules in girls aged 9–14 years: a randomized trial. J Infect Dis. 2017;215(11):1711-9. https://doi.org/10.1093/ infdis/jix154

  30. Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila). 2013;6(11):1242-50. https://doi. org/10.1158/1940-6207.CAPR-13-0203

  31. LaMontagne DS, Mugisha E, Pan Y, Kumakech E, Ssemaganda A, Kemp TJ, et al. Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda. Vaccine. 2014;32(47):6303-11. https:// doi.org/10.1016/j.vaccine.2014.08.071

  32. Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol. 2016;17(1):67-77. https://doi.org/10.1016/ S1470-2045(15)00414-3

  33. Stanley MA, Sudenga SL, Giuliano AR. Alternative dosage schedules with HPV virus-like particle vaccines. Expert Rev Vaccines. 2014;13(8):1027-38. https://doi.org/10.1586/14760584.2014.935767

  34. Romanowski B, Schwarz TF, Ferguson LM, Ferguson M, Peters K, Dionne M. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. Hum Vaccines Immunother. 2014;10(5):1155-65. https://doi.org/10.4161/hv.28022

  35. Safaeian M, Sampson JN, Pan Y, Porras C, Kemp TJ, Herrero R, et al. Durability of protection afforded by fewer doses of the HPV16/18 vaccine: the CVT trial. J Natl Cancer Inst. 2018;110(2). https://doi. org/10.1093/jnci/djx158

  36. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol. 2015;16(7):775-86. https://doi.org/10.1016/S1470-2045(15)00047-9

  37. Cuschieri K, Kavanagh K, Moore C, Bhatia R, Love J, Pollock KG. Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis. Br J Cancer. 2016;114(11):1261-4. https://doi. org/10.1038/bjc.2016.97

  38. Pollock KG, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer. 2014;111(9):1824-30. https://doi.org/10.1038/bjc.2014.479

  39. Herweijer E, Leval A, Ploner A, Eloranta S, Simard JF, Dillner J. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA. 2014;311(6):597-603. https:// doi.org/10.1001/jama.2014.95

  40. Crowe E, Pandeya N, Brotherton JML, Dobson AJ, Kisely S, Lambert SB, Whiteman DC. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ. 2014;348:g1458. https://doi.org/10.1136/bmj.g1458

  41. Gertig DM, Brotherton JML, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 2013;11(1):227. https://doi. org/10.1186/1741-7015-11-227

  42. Brotherton JML, Malloy M, Budd AC, Saville M, Drennan KT, Gertig DM. Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia. Papillomavirus Res. 2015;(1):59-73. https://doi. org/10.1016/j.pvr.2015.05.005

  43. Sankaranarayanan R, Joshi S, Muwonge R, Esmy PO, Basu P, Prabhu P, et al. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. Vaccine. 2018;36(32 Pt A):4783-91. https://doi.org/10.1016/j.vaccine.2018.02.087

  44. Castellsagué X, Naud P, Chow SN, Wheeler CM, Germar MJ, Lehtinen M, et al. Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA. J Infect Dis. 2014;210(4):517-34. https://doi.org/10.1093/infdis/jiu139

  45. Kreimer AR, Sherman ME, Sahasrabuddhe VV, Safaeian M. The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents. J Natl Cancer Inst. 2015;107(3):pii:dju436. https://doi.org/10.1093/jnci/dju436

  46. National Cancer Institute (NCI). Scientific evaluation of one or two doses of the bivalent or nonavalent prophylactic HPV vaccines. ClinicalTrials. gov, 2017 [internet] [cited 2017, Aug 18]. Available from: https://clinicaltrials. gov/ct2/show/NCT03180034

  47. Salmerón J, Torres-Ibarra L, Bosch FX, Cuzick J, Lörincz A, Wheeler CM. HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico. Salud Publica Mex. 2016;58(2):211-9. https://doi.org/10.21149/spm.v58i2.7790

  48. Bosch FX, Robles C, Díaz M, Arbyn M, Baussano I, Clavel C, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol. 2016;13(2):119-32. https://doi.org/10.1038/nrclinonc. 2015.146




2020     |     www.medigraphic.com